Evropska unija - litovščina - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumabas - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatito veikėjai, išskyrus kortikosteroidus - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Evropska unija - litovščina - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunosupresantai - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Evropska unija - litovščina - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengės - vakcinos - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 ir 4. naudoti dengvaxia turėtų būti laikantis oficialių rekomendacijų.

Evropska unija - litovščina - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) yra skirtas pirminio ir tarpinio detonatoriaus vakcinacijos kūdikiams ir mažiems vaikams nuo šešių savaičių amžiaus nuo difterijos, stabligės, kokliušo, hepatito b, poliomielito ir invazinės b tipo haemophilus influenzae (hib) sukeliamų ligų. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Evropska unija - litovščina - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vakcinos - hexyon (dtap-ipv-hb-hib) yra skirtas pirminio ir tarpinio detonatoriaus vakcinacijos kūdikiams ir mažiems vaikams nuo šešių savaičių amžiaus nuo difterijos, stabligės, kokliušo, hepatito b, poliomielito ir invazinės b tipo haemophilus influenzae (hib) sukeliamų ligų. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Evropska unija - litovščina - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - gripas, žmogus - vakcinos - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Evropska unija - litovščina - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vakcinos - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ir 5. 1 in product information document). naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi winthrop industrie - levofloksacinas - plėvele dengtos tabletės - 500 mg - levofloxacin

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi winthrop industrie - hidroksichlorokvino sulfatas - plėvele dengtos tabletės - 200 mg - hydroxychloroquine

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi pasteur - a gr. neisseria meningitidis polisacharidas/c gr. neisseria meningitidis polisacharidas - milteliai ir tirpiklis injekcinei suspensijai užpildytame švirkšte - 50 µg/50 µg/0,5 ml - meningococcus a,c, bivalent purified polysaccharides antigen